Nano and liposome cancer chemotherapy: A review of advances in drug delivery with applications.

The high incidence of malignant tumors continues to pose a significant threat to public health. In recent years, there have been notable advancements in tumor treatment methods, leading to substantial changes in the concepts and clinical approaches to treatment. The primary clinical methods for treating malignant tumors currently include surgical resection, radiation therapy, and chemotherapy. Among these, chemotherapy is one of the most crucial and comprehensive treatment strategies. The rapid progress in nanoscience has fostered the development of nanocarrier compounds and their clinical applications in disease treatment. Notably, nanomedicines, including goserelin sustained-release implants, doxorubicin liposomes, albumin-bound paclitaxel, and paclitaxel liposomes, have been effectively utilized in tumor treatment in China [1]. The article presents a comprehensive overview of recent advancements in utilizing various nanocarriers for combination therapy in tumors. It also examines the clinical application and efficacy of drug delivery carriers. The development of efficient and safe co-delivery systems that facilitate the effective transport and precise release of drugs within the cancerous tissues while also elucidating the internalization of nanoparticles into tumor cells and their functional mechanisms represents critical areas for future research. Concurrently, advancements in nanocarriers and tumor treatment are anticipated to yield superior therapeutic outcomes and improved quality of life for cancer patients.